NASDAQ:VCNX Vaccinex (VCNX) Stock Price, News & Analysis $2.55 -0.27 (-9.57%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Vaccinex Stock (NASDAQ:VCNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaccinex alerts:Sign Up Key Stats Today's Range$2.50▼$2.8550-Day Range$2.58▼$8.5652-Week Range$2.50▼$18.06Volume78,342 shsAverage Volume38,258 shsMarket Capitalization$4.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.Read More… Golden Equation: Volatility = Opportunity (Ad)When the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when the market takes a dive, my students get excited… Why? Because I've taught them how they can turn market volatility into opportunity! Click here to reserve your free seat now. Vaccinex Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks22nd Percentile Overall ScoreVCNX MarketRank™: Vaccinex scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Vaccinex.Read more about Vaccinex's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaccinex is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaccinex is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Vaccinex's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.78% of the float of Vaccinex has been sold short.Short Interest Ratio / Days to CoverVaccinex has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaccinex has recently decreased by 5.01%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaccinex does not currently pay a dividend.Dividend GrowthVaccinex does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.78% of the float of Vaccinex has been sold short.Short Interest Ratio / Days to CoverVaccinex has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaccinex has recently decreased by 5.01%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added Vaccinex to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Vaccinex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,247,255.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders51.50% of the stock of Vaccinex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.11% of the stock of Vaccinex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vaccinex's insider trading history. Receive VCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter. Email Address VCNX Stock News HeadlinesWhat's Going On With Vaccinex Stock Wednesday?September 19, 2024 | msn.comVaccinex Announces Exercise of Warrants for $6.2 Million in Gross ProceedsSeptember 18, 2024 | globenewswire.comGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when the market takes a dive, my students get excited… Why? Because I've taught them how they can turn market volatility into opportunity! October 5, 2024 | Prosper Trading Academy (Ad)VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024August 14, 2024 | investorplace.comVaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development PartnershipAugust 14, 2024 | globenewswire.comVaccinex stock tanks 40% despite positive Alzheimer’s study updateJuly 31, 2024 | msn.comVaccinex stock plunges 24% on mixed results for Alzheimer's studyJuly 31, 2024 | msn.comVaccinex, Inc. (VCNX)July 25, 2024 | finance.yahoo.comSee More Headlines VCNX Stock Analysis - Frequently Asked Questions How have VCNX shares performed this year? Vaccinex's stock was trading at $9.3072 on January 1st, 2024. Since then, VCNX shares have decreased by 72.6% and is now trading at $2.55. View the best growth stocks for 2024 here. How were Vaccinex's earnings last quarter? Vaccinex, Inc. (NASDAQ:VCNX) issued its earnings results on Wednesday, August, 14th. The company reported ($3.10) earnings per share for the quarter. The firm had revenue of $0.23 million for the quarter. When did Vaccinex's stock split? Vaccinex's stock reverse split on Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Vaccinex IPO? Vaccinex (VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Vaccinex? Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vaccinex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL) and Pfizer (PFE). Company Calendar Last Earnings8/14/2024Today10/05/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VCNX CUSIPN/A CIK1205922 Webwww.vaccinex.com Phone(585) 271-2700Fax585-271-2765Employees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($82.8030) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,250,000.00 Net MarginsN/A Pretax Margin-4,987.92% Return on EquityN/A Return on Assets-446.07% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.42 Sales & Book Value Annual Sales$570,000.00 Price / Sales7.74 Cash FlowN/A Price / Cash FlowN/A Book Value($2.59) per share Price / Book-0.98Miscellaneous Outstanding Shares1,730,000Free Float768,000Market Cap$4.41 million OptionableNo Data Beta0.96 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:VCNX) was last updated on 10/5/2024 by MarketBeat.com Staff From Our PartnersThe panic button has already been pressedIf you missed it, my emergency election broadcast is now available on replay.Porter & Company | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.